FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response.	0.5								

					or S	Section	on 30(h) o	of the	Investment	Com	pany Act	of 1940							
Name and Address of Reporting Person* Rubin Jami					2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]								Relationship of Reporting Perso (Check all applicable) X Director				son(s) to Iss		
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023								Λ		(give title		Other (s below)	
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
				_									,	X Form filed by One Reporting Person					
(Street)													Form filed by More than One Reporting Person						
CAMBR	CAMBRIDGE MA 02139				- Ru	Rule 10b5-1(c) Transaction Indication													
(City)	(S	tate)	(Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									d to				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
						_			-	ısp									
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					r) E	xecution any	A. Deemed kecution Date, any lonth/Day/Year)		Transaction Dispose Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4		4 and Securitie Benefici Owned F		es Forr ally (D) of Following (I) (II		n: Direct or Indirect instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount (A) or (D)		or Pri	ce	Transact	Reported Fransaction(s) Instr. 3 and 4)		(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price or Derivative Security (Instr. 5)			ly G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$11.14	05/31/2023			A		66,055		(1)	05/	/30/2033	Common Stock	66,0	55	\$0.00	66,055		D	

Explanation of Responses:

1. This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Remarks:

/s/ Brian Adams, as Attorneyin-Fact ** Signature of Reporting Person

06/01/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.